High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam/avibactam

Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam

(2019) Elske Sieswerda et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016–18

(2019) Boppe Appalaraju et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae

(2018) Charles R. Dean et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program, 2012 to 2015

(2018) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization ofEscherichia coliNDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3

(2015) Richard A. Alm et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS